Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is named one of the 12 Best Genomics Stocks to Invest In. Cathie Wood’s ARK Investment purchased 755,000 shares of RXRX on December 19, 2025. JPMorgan upgraded RXRX from Neutral to Overweight with a $11 price target due to REC-4881’s effectiveness in treating familial adenomatous polyposis.

JPMorgan forecasts REC-4881 to have peak revenues over $1 billion with a 60% success rate. RXRX’s CDK7 inhibitor REC-617 shows promise in platinum-resistant ovarian cancer. The company maintains its 2025 expense forecast under $450 million and its 2026 forecast under $390 million, expecting to operate until 2027 without additional funding.

RXRX is a clinical-stage biotechnology company. While RXRX offers investment potential, other AI stocks may have greater upside with less risk. For undervalued AI stocks benefiting from current trends, see our report on the best short-term AI stock.

Read more at Yahoo Finance: Cathie Wood’s ARK Investment Buys 755K Shares Of Recursion Pharmaceuticals, Inc. (RXRX)